CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This dose comparison study, taking place at over 200 sites worldwide, will compare the
dosing, safety and efficacy of an investigational medicine OPC-6535 to the dosing, safety and
efficacy of Asacol ® in the maintenance of remission in subjects with ulcerative colitis.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.